SER

Announcements

Nothing here yet

Daily updates

• Serina's safety committee supported advancing SER-252 to Cohort 2 in Parkinson's diseaseSep 9, 2026

FDA designations

Nothing here yet

News

• Serina Therapeutics reported Cohort 1 observations from its registrational SER-252 study in advanced Parkinson's disease and advanced to Cohort 2Sep 9, 2026
• Serina Therapeutics completes enrollment and dosing in Cohort 1 of the registrational trial of SER-252 for advanced Parkinson's diseaseJul 23, 2026
• Serina Therapeutics received FDA IND clearance for SER-252 in advanced Parkinson'sJan 30, 2026
• Serina Therapeutics announces FDA feedback supports registrational trial design of SER-252 in advanced Parkinson's disease under 505(b)(2) NDA pathwayAug 26, 2025